Matinas BioPharma Holdings, Inc.

MTNB

Matinas BioPharma Holdings, Inc.

MTNB

Insider Sentiment (TTM):

Last Purchase:2020-08-21Last Sale:-Shares Purchased (TTM):0Shares Sold (TTM):0

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:354,389Shares Outstanding:6,406,191Institutional Ownership Pct.:5.53%

Earnings Market Reaction:

Filing Date:2026-08-13Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Cash And Cash Equivalents At Carrying Value	1	2	4	5	7	7	7	10	4	1	5	6
Assets Current
Assets Current	1	3	4	6	7	8	8	12	15	10	16	20
Marketable Securities Current	-	-	-	-	-	-	-	1	10	7	9	12
Restricted Cash Current	0	0	0	0	0	0	0	0	0	0	0	0
Prepaid Expense And Other Assets Current	0	0	0	0	1	1	1	1	1	2	2	2
Property Plant And Equipment Net	-	0	0	0	0	0	0	2	2	2	2	2
Assets Held In Trust Noncurrent	-	-	-	0	0	-	-	-	-	-	-	-
Operating Lease Right Of Use Asset	0	0	0	1	1	2	2	3	3	3	3	3
Finance Lease Right Of Use Asset	-	0	0	0	0	0	0	0	0	0	0	0
Assets Noncurrent
Assets Noncurrent	2	3	3	4	4	4	5	9	9	9	10	10
Intangible Assets Net Excluding Goodwill	2	2	2	2	2	2	2	3	3	3	3	3
Goodwill	-	-	-	-	-	-	-	1	1	1	1	1
Restricted Cash Noncurrent	-	0	0	0	0	0	0	0	0	0	0	0
Assets	3	6	7	10	11	12	13	21	24	20	25	30
Liabilities And Stockhold…
Accounts Payable Current	1	1	0	0	0	0	0	0	0	0	1	1
Accrued Liabilities And Other Liabilities	1	1	0	-	-	-	2	-	-	-	1	-
Operating Lease Liability Current	-	1	1	1	1	1	1	1	1	1	1	1
Accrued Liabilities Current	-	1	-	1	1	1	-	1	1	1	1	2
Liabilities Current
Liabilities Current	1	2	1	1	2	2	3	2	2	2	3	3
Finance Lease Liability Current	-	0	0	0	0	0	0	0	0	0	0	0
Deferred Income Tax Liabilities Net	0	0	0	0	0	0	0	0	0	0	0	0
Liabilities Noncurrent
Liabilities Noncurrent	0	1	1	2	2	4	2	3	3	3	3	3
Operating Lease Liability Noncurrent	-	0	1	1	2	2	2	2	3	3	3	3
Finance Lease Liability Noncurrent	-	0	0	0	0	0	0	0	0	0	0	0
Derivative Liabilities	-	-	-	-	-	1	-	-	-	-	-	-
Liabilities	2	3	2	3	4	6	5	5	5	5	6	7
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Stockholders Equity
Additional Paid In Capital Common Stock	216	216	216	215	214	208	207	207	206	196	195	194
Stockholders Equity	2	3	5	6	8	6	8	16	19	15	19	23
Retained Earnings Accumulated Deficit	-214	-213	-211	-209	-207	-201	-200	-191	-187	-181	-176	-170
Accumulated Other Comprehensive Income Loss Net Of…	-	-	-	-	-	-	-	-	-0	-0	-0	-0
Liabilities And Stockholders Equity	3	6	7	10	11	12	13	21	24	20	25	30
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0.001	-	-	-	-	-	-
Preferred Stock Shares Authorized	10	10	10	10	10	10	-	-	-	-	-	-
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	500	500	500	500	250	250	250	250	500	500	250	500
Common Stock Shares Issued	6	6	6	6	5	5	5	5	5	4	4	4
Shares Outstanding	6	6	6	6	5	5	5	5	5	4	4	4

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	26.96%	0.63%	-62.23%	-	-	-	-	-	-	-	-	-
2025	20.78%	19.09%	12.99%	4.24%	17.58%	-16.36%	-32.48%	-47.01%	-48.89%	22.00%	40.80%	20.80%
2024	-7.34%	-10.73%	-4.52%	-56.05%	-61.72%	-92.59%	-20.42%	-10.56%	-18.31%	21.55%	60.34%	58.10%
2023	-	-	-	-	-	-	-23.91%	-21.74%	-28.99%	-35.17%	-41.38%	-44.83%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	0.85	1.32	2.79	3.78	4.07	3.35	3.01	5.53	6.39	5.15	5.93	6.19
Quick Ratio	0.60	1.15	2.77	3.67	3.69	3.09	2.75	5.11	6.00	4.08	5.27	5.66
Working Capital	-207.00K	689.00K	2.61M	4.16M	5.48M	5.29M	5.36M	9.62M	12.89M	8.29M	12.92M	16.76M
Leverage & Debt
Debt to Equity	0.90	0.94	0.49	0.50	0.49	0.92	0.67	0.30	0.28	0.35	0.30	0.29
Debt Ratio	0.47	0.49	0.33	0.33	0.33	0.48	0.40	0.23	0.22	0.26	0.23	0.22
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.03	0.06
Per Share Metrics
Diluted EPS TTM	-1.04	-1.66	-1.89	-3.10	-3.85	-3.95	-4.98	-4.19	-4.59	-5.35	-5.28	-4.89
Free Cash Flow Per Share TTM	-1.00	-1.03	-1.28	-1.66	-2.17	-2.38	-3.26	-3.37	-3.59	-3.95	-3.57	-3.51
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-	-	-	-	-	-	-	-	-	-	-2,168.43%	-1,082.48%
Net Profit Margin TTM	-	-	-	-	-	-	-	-	-	-	-2,093.25%	-985.28%
Growth Metrics
Net Revenue Growth (1Y)	-	-	-	-	-	-	-100.00%	-100.00%	-100.00%	-100.00%	-65.62%	1.51%
Net Income Growth (1Y)	-65.88%	-47.17%	-57.34%	-20.19%	-14.42%	-13.63%	5.71%	-0.61%	10.85%	13.25%	9.26%	-11.63%
EPS Growth (1Y)	-72.90%	-58.05%	-62.08%	-26.03%	-16.10%	-26.19%	-5.60%	-14.28%	-3.41%	13.20%	9.04%	-11.80%
Valuation Metrics
P/E TTM	-0.59	-0.30	-0.31	-0.61	-0.23	-0.13	-0.10	-0.84	-1.72	-2.53	-2.05	-1.33
P/B TTM	2.18	1.06	0.66	1.59	0.59	0.42	0.33	1.13	2.06	4.05	2.44	1.22
P/S TTM	-	-	-	-	-	-	-	-	-	-	42.82	13.09
Market Cap	3.92M	3.20M	3.21M	10.27M	4.53M	2.65M	2.48M	17.83M	39.40M	58.90M	46.93M	28.24M
Enterprise Value	3.16M	812.10K	-784.16K	4.85M	-1.98M	-4.26M	-4.79M	7.56M	35.20M	57.85M	42.17M	21.86M
Calculated Values
Free Cash Flow TTM	-6.42M	-6.61M	-7.01M	-9.01M	-11.04M	-12.12M	-15.89M	-16.95M	-17.89M	-17.18M	-15.50M	-15.26M
Net Debt	-761.00K	-2.39M	-3.99M	-5.42M	-6.51M	-6.91M	-7.27M	-10.28M	-4.20M	-1.05M	-4.76M	-6.38M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2020-08-21Purchase

Owner: Stern, Adam K

Title: -

Shares: 20,000

Price/Share: $0.83

Value: $16,600.00

Shares Owned: 3,301,983

Relationship: Director

Ownership: Indirect

2020-05-14Purchase

Owner: Lepore, Patrick G

Title: -

Shares: 100,000

Price/Share: $0.73

Value: $73,000.00

Shares Owned: 400,000

Relationship: Director

Ownership: Direct

2020-03-17Purchase

Owner: Jabbour, Jerome D

Title: President and CEO

Shares: 10,000

Price/Share: $0.65

Value: $6,500.00

Shares Owned: 799,511

Relationship: Director,Officer

Ownership: Direct

2020-03-17Purchase

Owner: Stern, Adam K

Title: -

Shares: 10,000

Price/Share: $0.65

Value: $6,500.00

Shares Owned: 10,000

Relationship: Director

Ownership: Indirect

2019-11-25Purchase

Owner: Kucinski, Keith A

Title: Chief Financial Officer

Shares: 58,000

Price/Share: $1.23

Value: $71,340.00

Shares Owned: 94,500

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2020-08-21	Stern, Adam K	Director	-	Indirect	Purchase	20,000	0.83	$16,600.00	3,301,983	4
2020-05-14	Lepore, Patrick G	Director	-	Direct	Purchase	100,000	0.73	$73,000.00	400,000	4
2020-03-17	Jabbour, Jerome D	Director,Officer	President and CEO	Direct	Purchase	10,000	0.65	$6,500.00	799,511	4
2020-03-17	Stern, Adam K	Director	-	Indirect	Purchase	10,000	0.65	$6,500.00	10,000	4
2019-11-25	Kucinski, Keith A	Officer	Chief Financial Officer	Direct	Purchase	58,000	1.23	$71,340.00	94,500	4
2019-11-15	Lepore, Patrick G	Director	-	Direct	Purchase	100,000	1.06	$106,000.00	300,000	4
2019-08-20	Ende, Eric J	Director	-	Direct	Purchase	20,000	0.66	$13,200.00	109,292	4
2019-08-19	Stern, Adam K	Director	-	Direct	Purchase	10,400	0.70	$7,280.00	804,392	4
2019-08-19	Ende, Eric J	Director	-	Direct	Purchase	20,000	0.68	$13,600.00	89,292	4
2019-08-19	Jabbour, Jerome D	Director,Officer	President and CEO	Direct	Purchase	14,650	0.68	$9,962.00	786,511	4
2019-08-16	Lepore, Patrick G	Director	-	Direct	Purchase	100,000	0.72	$72,000.00	200,000	4
2019-06-14	Stern, Adam K	Director	-	Indirect	Purchase	15,000	0.80	$12,000.00	3,239,483	4
2019-06-12	Jabbour, Jerome D	Director,Officer	President and CEO	Direct	Purchase	12,487	0.80	$9,989.60	771,861	4
2019-06-12	Stern, Adam K	Director	-	Indirect	Purchase	20,000	0.80	$16,000.00	3,224,483	4
2019-06-10	Stern, Adam K	Director	-	Indirect	Purchase	15,000	0.82	$12,300.00	3,204,483	4
2019-06-07	Stern, Adam K	Director	-	Indirect	Purchase	20,000	0.89	$17,800.00	3,189,483	4
2019-05-31	Stern, Adam K	Director	-	Indirect	Purchase	80,000	0.94	$75,200.00	3,169,483	4
2019-05-16	Lepore, Patrick G	Director	-	Direct	Purchase	100,000	0.95	$95,000.00	100,000	4
2019-05-16	Stern, Adam K	Director	-	Indirect	Purchase	150,000	0.95	$142,500.00	3,089,483	4
2019-05-16	Conrad, Herbert J	Director	-	Indirect	Purchase	25,000	0.96	$24,000.00	172,959	4
2017-09-11	Mannino, Raphael J	Officer	Chief Scientific Officer	Direct	Purchase	5,000	1.41	$7,050.00	1,424,565	4
2017-09-08	Stern, Adam K	Director	-	Indirect	Purchase	50,000	1.38	$69,000.00	3,689,483	4
2017-09-08	Rongen, Roelof	Director,Officer	Chief Executive Officer	Direct	Purchase	5,000	1.36	$6,800.00	3,539,416	4
2017-09-07	Conrad, Herbert J	Director	-	Direct	Purchase	100,000	1.30	$130,000.00	3,879,600	4
2017-09-07	Scibetta, James S	Director	-	Direct	Purchase	5,000	1.29	$6,450.00	418,309	4
2017-09-07	Ferrari, Stefano	Director	-	Direct	Purchase	5,000	1.24	$6,200.00	203,984	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

5.53%

Inst. Shares: 354,389

Shares Outstanding: 6,406,191

2025-12-31

7.80%

Inst. Shares: 426,918

Shares Outstanding: 5,474,129

2025-09-30

5.28%

Inst. Shares: 286,855

Shares Outstanding: 5,435,829

2025-06-30

5.43%

Inst. Shares: 276,376

Shares Outstanding: 5,086,985

2025-03-31

5.66%

Inst. Shares: 287,671

Shares Outstanding: 5,086,985

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	354,389	6,406,191	5.53%
2025-12-31	426,918	5,474,129	7.80%
2025-09-30	286,855	5,435,829	5.28%
2025-06-30	276,376	5,086,985	5.43%
2025-03-31	287,671	5,086,985	5.66%
2024-12-31	336,994	4,865,829	6.93%
2024-09-30	545,573	5,037,829	10.83%
2024-06-30	36,846,402	4,987,019	-
2024-03-31	23,056,904	4,347,162	-
2023-12-31	23,061,418	4,345,291	-
2023-09-30	23,740,437	4,345,291	-
2023-06-30	23,278,485	4,345,291	-
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Matinas BioPharma Holdings, Inc. (MTNB) — SEC Financial Statements & Analysis

Matinas BioPharma Holdings, Inc. (MTNB) is a pharmaceutical preparations company, incorporated in DE. Matinas BioPharma Holdings, Inc. trades on NYSE as: MTNB. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Matinas BioPharma Holdings, Inc. reported a -100.00% year-over-year revenue growth, a Debt-to-Equity ratio of 0.90x, a Price-to-Sales (P/S) ratio of 42.82x (TTM), a Price-to-Book (P/B) ratio of 2.18x (TTM), at a market cap of $3.92M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -100.00%
Debt To Equity: 0.90x
P/S TTM: 42.82x
P/B TTM: 2.18x
Market Cap: $3.92M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Matinas BioPharma Holdings, Inc. in?

Matinas BioPharma Holdings, Inc. (MTNB) operates in the Pharmaceutical Preparations industry.

What is MTNB's market cap?

Matinas BioPharma Holdings, Inc. (MTNB) has a market capitalization of $3.92M as of 2026-06-30.

What exchange does MTNB trade on?

Matinas BioPharma Holdings, Inc. (MTNB) trades on the NYSE.

Where is Matinas BioPharma Holdings, Inc. incorporated?

Matinas BioPharma Holdings, Inc. is incorporated in DE.